Global Lateral Epicondylitis Treatment Market Assessment, By Treatment Type [Non-surgical Treatment, Surgical Treatment], By Age Group [Pediatric, Adult, Geriatric], By End-user [Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Homecare Settings, Others], By Region, Opportunities and Forecast, 2018-2032F

Global lateral epicondylitis treatment market is projected to witness a CAGR of 6.05% during the forecast period 2025-2032, growing from USD 1.47 billion in 2024 to USD 2.35 billion in 2032. Rising prevalence of elbow tendons swelling, coupled with increasing incidences of pain in elbow joints, are the major factors driving the global market. The repetitive motion of the elbow and arms is the main reason for tennis elbow (lateral epicondylitis).

Report Attribute	Details
Base Year	2024
Forecast Period	2025-2032F
Historical Period	2018-2023
Projected Growth Rate	CAGR of 6.05% between 2024 and 2032
Revenue Forecast in 2032	USD 2.35 billion

Global lateral epicondylitis treatment market experiences consistent growth because of increasing repetitive strain injury numbers and growing sports participation, and an aging workforce facing musculoskeletal problems. Lateral epicondylitis, or tennis elbow, is a medical condition that causes pain together with inflammation at the outer elbow due to repeated forearm muscles. The market contains various treatment methods, which include surgical procedures and non-surgical options, but patients choose non-surgical approaches, including physiotherapy and NSAIDs, as well as corticosteroid injections, PRP and orthotic bracing, together with shockwave therapy, because these treatments are less invasive and more people are choosing them. The market experiences growth thanks to technological developments, which include regenerative medicine along with wearable elbow braces and extracorporeal shockwave therapy (ESWT) devices. The global market finds its leading position in North America because of advanced healthcare systems and elevated public awareness, yet the Asia-Pacific region shows the fastest market growth because of rising physiotherapy and outpatient care availability. The future market opportunities will emerge from increased early diagnosis initiatives and better physical therapy insurance coverage, and PRP and biologics clinical research. The competitive environment consists of pharmaceutical companies, medical device manufacturers and therapy services providers who develop products to improve patient results while shortening recovery periods and expanding their business into global markets.

For instance, in February 2025, CollPlant announced that it expanded the distribution channels for its Vergenix STR product in Europe and Asia. Vergenix STR is based on the Company's rhCollagen technology and is used for the treatment of tendinopathy that promotes healing and repair of tendon injuries to various tendons, including elbow tendons (for treating tennis elbow), rotator cuffs, patellar tendons, achilles tendons, and hand tendons.

Rising Cases of Bone Injuries Boost Market Demand

The rising cases of bone-related injuries are a major factor driving growth in the lateral epicondylitis treatment market. As more individuals participate in physically demanding activities such as sports, fitness, and manual labor, the incidence of injuries to bones (fractures, stress injuries, and damage to the joints) has steadily increased. Bone injuries can lead to compensation by surrounding muscles and tendons, resulting in lateral epicondylitis. Second, individuals recovering from bone injuries often develop secondary complications due to improper movement or stressing and straining unaffected limbs. This increased demand for orthopedic care, physiotherapy, and rehabilitation creates a demand for recovery of significant magnitude (braces, shockwave treatment, and/or non-invasive pain management). Thus, the demand for improved recovery options has led to better treatment options. Healthcare providers have also included the ability to demand comprehensive musculoskeletal care, which creates demand for growth opportunities for the lateral epicondylitis treatment market.

For instance, in January 2025, Journavx (suzetrigine), an oral tablet formulation of 50 mg, became the first non-opioid analgesic to be approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe acute pain in adults. Journavx is the first drug in the new class of approved pain management agents. Such a tablet immediately acts and reduces pain.

Increase in the Number of Sport Activities Support Market Expansion

The growing sports participation across the world is increasing demand for the lateral epicondylitis treatment market. As we emphasize health, fitness, and recreation more, participation in sports is increasing, including sports such as tennis, badminton, golf, and weight training, all of which can involve repeated arm movement, placing strain on the forearm tendons. An increase in physical activity and sport participation will increase overuse injuries such as lateral epicondylitis, also known as tennis elbow. Both amateur and professional athletes want effective, non-invasive solutions for lateral epicondylitis that work and have a minimal recovery time, allowing athletes to get back in action very quickly. More and more demand from athletes to return to sport means there's more of a demand for physiotherapy, orthopedic bracing, platelet-rich plasma (PRP) injections, and shockwave therapy. Sports clinics, fitness facilities, and physiotherapy providers are expanding services to meet demand and interest. The idea of an active and fit lifestyle for sport participation/or exercise is a growing trend. The increase in sport participation for clinicians and researchers of all ages helps to grow the market and especially for lateral epicondylitis treatment.

For instance, according to the newly published Sports & Fitness Industry Association (SFIA) Topline Participation Report in 2023 highlights that 242 million Americans, or 78.8% of Americans, have participated in an activity once or more (up 2.2% from last year). Participation has increased year after year (10 straight years), increasing an additional 5 million participants in activities in 2023.

Non-Surgical Treatment Holds the Largest Market Share

Non-surgical treatment holds the largest share of the lateral epicondylitis treatment market segment because of its convenient access, together with better safety and proven clinical results. Tennis elbow patients find conservative treatment approaches, including physiotherapy, NSAIDs, and corticosteroid injections along with PRP therapy, orthotic bracing and ESWT to be effective for the majority of cases. Patients benefit from these treatment methods because they experience shorter recovery times, along with reduced side effects, and they avoid surgical complications. The growing patient preference for early intervention, combined with better physiotherapy facilities, leads most patients to choose non-invasive treatments as their initial approach. The development of wearable technological devices, which include smart braces and app-connected therapy tools makes non-surgical care more effective and attractive to patients. The widespread availability of outpatient medical facilities, together with insurance coverage support in various regions, strengthens the position of non-surgical treatment methods. The patient trend for minimally invasive treatments will make this segment maintain its dominant position in the future.

For instance, in May 2023, the FDA approved VibraCool, a new ice and vibration wearable, for the treatment of pain due to muscle tension and restriction in Tennis Elbow (tendinitis). Unlike opioids, electrical stimulation, VibraCool is non-invasive, drug-free, and portable.

North America Dominates the Lateral Epicondylitis Treatment Market

North America dominates the lateral epicondylitis treatment market because of its advanced healthcare system, combined with high condition awareness and advanced treatment accessibility. Tennis elbow affects many people in North America because the region has a large population of athletes, combined with workers who perform repetitive manual tasks. Patients living in North America have quick access to multiple non-surgical treatments, including physiotherapy together with corticosteroid injections and platelet-rich plasma (PRP), and shockwave therapy. The market receives additional strength from leading medical device manufacturers and sports medicine clinics as well as rehabilitation centers. Early diagnosis and treatment receive support from insurance coverage that is favorable and clinical guidelines that follow evidence-based practices. The region experiences faster adoption of orthotic device technology and regenerative medicine because of its strong healthcare innovation investments. North America holds the leading market position and innovation leadership for lateral epicondylitis treatment because of its aging yet physically active population and increasing emphasis on outpatient healthcare.

For instance, according to the Bureau of Labor Statistics (BLS), United States Department of Labor, reported private industry employers noted 2.6 million nonfatal injuries and illnesses in 2023, a decrease of 8.4% from 2022. These injuries led to an increased call for advanced treatment in the region and helped researchers develop innovative drugs in clinical trials on humans.

Download Free Sample Report

Impact of U.S. Tariffs on Lateral Epicondylitis Treatment Market

• The supply chains for lateral epicondylitis treatment devices and biologic therapies have undergone subtle changes because of U.S. tariffs. The increased import expenses for shockwave machines, together with smart braces and diagnostic equipment from overseas suppliers, have led to higher operational costs for healthcare providers.
• The response from major manufacturers involves supplier diversification and domestic production relocation, yet small clinics and specialized device producers find it difficult to handle the extra costs.
• Tariff enforcement uncertainty has created delays in product development and rollout processes, which have reduced the pace of innovation adoption.
• The uncertainty surrounding trade policies makes providers reluctant to replace their current equipment or purchase new orthotic devices.
• The changes occurring at the industry level might lead to increased treatment expenses and reduced availability of advanced solutions, even though patients currently experience standard care quality.

Report Scope

“Global Lateral Epicondylitis Treatment Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global lateral epicondylitis treatment market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecasts between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Treatment Type, Age Group, End-user
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profiled	Pfizer, Inc., GlaxoSmithKline plc, 3M Company, Merck & Co. Inc., Bayer AG, Cipla Inc., Novartis AG, Embla Medical hf., Zimmer Biomet Holdings, Inc., Enovis Corporation (DJO, LLC)
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global lateral epicondylitis treatment market has been segmented into the following categories: 

• By Treatment Type
  • Non-surgical Treatment
    • Medications
    • Physical Therapy
    • Orthotics and Braces
    • Others
  • Surgical Treatment
    • Arthroscopic Surgery
    • Open Surgery
    • Others
  • By Age Group
    • Pediatric
    • Adult
    • Geriatric
  • By End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Orthopedic Clinics
    • Homecare Settings
    • Others
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • South America
    • Middle East and Africa

Key Players Landscape and Outlook

The competitive landscape of the lateral epicondylitis treatment market is characterized by companies focusing on innovation, creating new product variants, and expanding globally. The market grows because of new non-surgical solutions, which include regenerative therapies together with wearable orthotic devices and shockwave therapy equipment. Companies increase their market presence by conducting research activities and developing clinical partnerships while entering expanding markets. Their competitive advantage stems from strategic efforts, which include launching new products and implementing digital therapy solutions along with providing better patient support services. The future outlook appears positive because emerging technological developments will maintain continuous market expansion along with growing consumer preference for noninvasive treatment methods.

In September 2024, the Food and Drug Administration approved Zynex Inc.’s new TensWave device, which matches Zynex's commitment to delivering complete pain management solutions. The recent FDA approval expands Zynex pain management product selection while continuing its goal of enhancing patient results using innovative medical devices.

Key Players Operating in Global Lateral Epicondylitis Treatment Market are:

• Pfizer, Inc.
• GlaxoSmithKline plc
• 3M Company
• Merck & Co., Inc.
• Bayer AG
• Cipla Inc.
• Novartis AG
• Embla Medical hf.
• Zimmer Biomet Holdings, Inc.
• Enovis Corporation (DJO, LLC)

If you can't find what you're searching for or have any custom requirements for global lateral epicondylitis treatment market, you may approach our team at info@marketsandata.com.